{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T17:07:31Z","timestamp":1740157651556,"version":"3.37.3"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Allergy Asthma Clin Immunol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most commonly used classes of medications, and are among the leading causes of drug hypersensitivity. NSAIDs hypersensitivity reactions are classified by symptom involvement and NSAIDs subclass cross-reactivity. Reactions varying from cutaneous involvement to respiratory symptoms can be triggered by multiple NSAIDs subclasses. Anaphylaxis, while rare, can be induced by a single NSAID, with tolerability of other structurally unrelated subclasses. Reactions that fall outside of these traditional categories are deemed \u201cblended reactions\u201d. We report a unique case of possible anaphylaxis to acetylsalicylic acid (ASA) and ibuprofen, two structurally dissimilar NSAIDs, indicating a severe blended reaction outside of the typical NSAIDs hypersensitivity reaction categories.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>An otherwise healthy 45 year old woman was referred to the Allergy and Immunology clinic after developing acute onset dyspnea, lip swelling, and generalized urticaria with ibuprofen use requiring treatment with intramuscular epinephrine in the emergency department. She previously tolerated ibuprofen, naproxen, and acetaminophen and had no history of urticaria, angioedema, asthma, or nasal polyps. She underwent an oral challenge to ASA whereby she developed urticaria and throat irritation with rebound symptoms requiring 2 doses of intramuscular epinephrine. On subsequent visits she passed treatment dose acetaminophen and celecoxib challenges. She was counseled to avoid all other NSAIDs and ASA desensitization was offered should this medication be clinically indicated in the future.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>NSAIDs hypersensitivity reactions can be triggered by individual NSAIDs with tolerance of other subclasses or by multiple structurally unrelated NSAIDs due to COX-1 inhibition. Determining the type of reaction (NERD, NECD, NIUA, SNIUAA, or SNIDHR) allows for appropriate oral challenges and safe alternative therapy recommendations. However, not all clinical reactions fit perfectly into these categories. Patients may also develop blended reactions. Our case highlights a severe blended reaction to multiple unrelated NSAIDs, including likely anaphylaxis to ASA. We note the utility of drug provocation tests (DPTs) to identify safe alternative medication options, as well as the importance of performing DPTs in settings properly equipped to assess and manage severe hypersensitivity reactions including anaphylaxis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13223-023-00830-2","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T16:17:12Z","timestamp":1694189832000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A case of possible anaphylaxis to ASA and structurally unrelated NSAIDs"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9272-2198","authenticated-orcid":false,"given":"Sarah","family":"Edgerley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harold","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,8]]},"reference":[{"key":"830_CR1","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/pai.12915","volume":"29","author":"M Kidon","year":"2018","unstructured":"Kidon M, Blanca-L\u00f3pez N, Gomes E, Terreehorst I, Tanno L, Ponvert C, et al. EAACI\/ENDA position paper: diagnosis and management of hypersensitivity reactions to non-steroidal anti-inflammatory drugs (NSAIDs) in children and adolescents. Pediatr Allergy Immunol. 2018;29:469\u201380.","journal-title":"Pediatr Allergy Immunol"},{"key":"830_CR2","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1111\/all.12260","volume":"68","author":"ML Kowalski","year":"2013","unstructured":"Kowalski ML, Asero R, Bavbek S, Blanca M, Blanca- L\u00f3pez N, Bochenek G, et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy. 2013;68:1219\u201332.","journal-title":"Allergy"},{"issue":"3","key":"830_CR3","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.18203\/2349-2902.isj20162769","volume":"3","author":"G Liu","year":"2016","unstructured":"Liu G, Jia Z, Lu J, Ma J, Jiang J. Rescue of anaphylaxis after oral aspirin ingestion. Int Surg J. 2016;3(3):1659\u201362.","journal-title":"Int Surg J"},{"key":"830_CR4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s11882-023-01064-3","volume":"23","author":"E Minaldi","year":"2023","unstructured":"Minaldi E, Cahill K. Recent updates in understanding NSAID hypersensitivity. Curr Allergy Asthma Rep. 2023;23:181\u20133.","journal-title":"Curr Allergy Asthma Rep"},{"issue":"1","key":"830_CR5","doi-asserted-by":"publisher","first-page":"16710","DOI":"10.1038\/s41598-018-34668-1","volume":"8","author":"I Do\u00f1a","year":"2018","unstructured":"Do\u00f1a I, Barrionuevo E, Salas M, Laguna JJ, Ag\u00fandez J, Garc\u00eda-Mart\u00edn E, et al. NSAIDs-hypersensitivity often induces a blended reaction pattern involving multiple organs. Sci Rep. 2018;8(1):16710\u201319.","journal-title":"Sci Rep"},{"key":"830_CR6","doi-asserted-by":"publisher","first-page":"112","DOI":"10.18176\/jiaci.0287","volume":"29","author":"J S\u00e1nchez Jorge","year":"2019","unstructured":"S\u00e1nchez Jorge J, S\u00e1nchez A, Cardona R. Prevalence of drugs as triggers of exacerbations in chronic urticaria. J Investig Allergol Clin Immunol. 2019;29:112\u20137.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"830_CR7","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/all.14032","volume":"75","author":"I Do\u00f1a","year":"2020","unstructured":"Do\u00f1a I, P\u00e9rez-S\u00e1nchez N, Eguiluz-Gracia I, Mu\u00f1oz-Cano R, Bartra J, Jos\u00e9 Torres M, et al. Progress in understanding hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. Allergy. 2020;75:561\u201375.","journal-title":"Allergy"},{"key":"830_CR8","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1111\/j.1398-9995.2011.02684.x","volume":"66","author":"I Do\u00f1a","year":"2011","unstructured":"Do\u00f1a I, Blanca-L\u00f3pez N, Jagemann LR, Torres MJ, Rond\u00f3n C, Fern\u00e1ndez J, et al. Response to a selective COX-2 inhibitor in patients with urticaria\/angioedema induced by nonsteroidal anti-inflammatory drugs. Allergy. 2011;66:1428\u201333.","journal-title":"Allergy"},{"key":"830_CR9","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1365-2222.2010.03651.x","volume":"41","author":"I Do\u00f1a","year":"2011","unstructured":"Do\u00f1a I, Blanca-L\u00f3pez N, Garc\u00eda-Mart\u00edn E, Torres MJ, Laguna JJ, Fern\u00e1ndez J, et al. Characteristics of subjects experiencing hypersensitivity to non-steroidal anti-inflammatory drugs: patterns of response. Clin Exp Allergy. 2011;41:86\u201395.","journal-title":"Clin Exp Allergy"},{"issue":"8","key":"830_CR10","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1016\/j.jaip.2019.04.042","volume":"7","author":"L Li","year":"2019","unstructured":"Li L, Laidlaw T. Cross-reactivity and tolerability of celecoxib in adult patients with NSAID hypersensitivity. J Allergy Clin Immunol Pract. 2019;7(8):2891\u20132893e4.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"830_CR11","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.5415\/apallergy.2018.8.e38","volume":"8","author":"BY Thong","year":"2018","unstructured":"Thong BY. Nonsteroidal anti-inflammatory drug hypersensitivity in the Asia-Pacific. Asia Pac Allergy. 2018;8:e38.","journal-title":"Asia Pac Allergy"},{"issue":"2","key":"830_CR12","doi-asserted-by":"publisher","first-page":"138","DOI":"10.2500\/aap.2013.34.3644","volume":"34","author":"AA White","year":"2013","unstructured":"White AA, Stevenson DD, Woessner KM, Simon RA. Approach to patients with aspirin hypersensitivity and acute cardiovascular emergencies. Allergy Asthma Proc. 2013;34(2):138\u201342.","journal-title":"Allergy Asthma Proc"},{"issue":"10","key":"830_CR13","first-page":"1131","volume":"167","author":"JM Wright","year":"2022","unstructured":"Wright JM. The double-edged sword of COX-2 selective NSAIDs. CMAJ. 2022;167(10):1131\u20137.","journal-title":"CMAJ"}],"container-title":["Allergy, Asthma &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-023-00830-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13223-023-00830-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-023-00830-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T13:17:41Z","timestamp":1700486261000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacijournal.biomedcentral.com\/articles\/10.1186\/s13223-023-00830-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,8]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["830"],"URL":"https:\/\/doi.org\/10.1186\/s13223-023-00830-2","relation":{},"ISSN":["1710-1492"],"issn-type":[{"type":"electronic","value":"1710-1492"}],"subject":[],"published":{"date-parts":[[2023,9,8]]},"assertion":[{"value":"4 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethics approval was required for the generation of this report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent from the patient was received for participation and publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SE has no competing interests to declare. HK reports Medical lecturer and\/or advisory boards: ALK, AstraZeneca, Bausch Health, CSL Behring, GSK, Miravo, Novartis, Medexus, Pfizer, Sanofi, Shire, Takeda. Editor-in-Chief of Allergy, Asthma and Clinical Immunology.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"81"}}